Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. (2009)
http://meetinglibrary.asco.org/content/35603-65
Results: Median follow-up time for the 21 patients still alive was 112 months (range, 104-126 months). Blood samples were collected in 10/21 subjects and 6/8 (75%) evaluble patients had persistent T-cell immunity to immunizing HER2 peptides; and 7/8 patients (88%) had T-cell immunity specific for HER2 protein and peptides not contained in their immunizing mix (defined as ES). In multivariate analysis, number of chemotherapy regimens prior to vaccination (HR=5.7 (CI 95%, 1.5-23; p=<0.001)), and development of ES after HER2 vaccination (HR=0.34 (CI 95%, 0.12-1.0; p=0.05)) were independent predictors of OS. Median OS for 33 subjects who developed ES was 84 months vs 25 months for 16 subjects who did not develop ES
Threaded Mode